Management of hepatic metastasis from colorectal cancers: An update

Sharad Sharma, Cemalettin Camci, Nicolas Jabbour

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Approximately 50%-60% of patients with colorectal cancers will develop liver lesions in their life span. Despite the potential of surgical resection to provide long-term survival in this subset of patients, only 15%-20% are found to be resectable. The introduction of new neoadjuvant chemotherapeutic agents and the expanding criteria of resection have enhanced the overall 5-year survival from 30% to 60% in the past decade. The use of technical innovations such as staged resection; portal vein embolization, and repeat resection have allowed higher resection rates in patients with bilobar disease. Extrahepatic primary and liver-exclusive recurrent disease no longer represent an absolute contraindication to resection. The role of regional therapy using hepatic arterial infusion is being redefined for liver-exclusive unresectable disease. Adjuvant chemotherapy in combination with regional therapies is being looked at from fresh perspectives. Ablative approaches have gained a firm role both as an adjunct to surgical resection and in the management of patients who are not surgical candidates. Overall, the management of hepatic metastasis from colorectal cancers requires a multimodal approach.

Original languageEnglish (US)
Pages (from-to)570-580
Number of pages11
JournalJournal of Hepato-Biliary-Pancreatic Surgery
Volume15
Issue number6
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
Survival
Adjuvant Chemotherapy
Portal Vein
Therapeutics

Keywords

  • Cancer
  • Colorectal
  • Hepatic
  • Metastasis

ASJC Scopus subject areas

  • Surgery
  • Hepatology

Cite this

Management of hepatic metastasis from colorectal cancers : An update. / Sharma, Sharad; Camci, Cemalettin; Jabbour, Nicolas.

In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 15, No. 6, 2008, p. 570-580.

Research output: Contribution to journalArticle

Sharma, Sharad ; Camci, Cemalettin ; Jabbour, Nicolas. / Management of hepatic metastasis from colorectal cancers : An update. In: Journal of Hepato-Biliary-Pancreatic Surgery. 2008 ; Vol. 15, No. 6. pp. 570-580.
@article{aca9a829b53d436c9244d0ecb1e9a308,
title = "Management of hepatic metastasis from colorectal cancers: An update",
abstract = "Approximately 50{\%}-60{\%} of patients with colorectal cancers will develop liver lesions in their life span. Despite the potential of surgical resection to provide long-term survival in this subset of patients, only 15{\%}-20{\%} are found to be resectable. The introduction of new neoadjuvant chemotherapeutic agents and the expanding criteria of resection have enhanced the overall 5-year survival from 30{\%} to 60{\%} in the past decade. The use of technical innovations such as staged resection; portal vein embolization, and repeat resection have allowed higher resection rates in patients with bilobar disease. Extrahepatic primary and liver-exclusive recurrent disease no longer represent an absolute contraindication to resection. The role of regional therapy using hepatic arterial infusion is being redefined for liver-exclusive unresectable disease. Adjuvant chemotherapy in combination with regional therapies is being looked at from fresh perspectives. Ablative approaches have gained a firm role both as an adjunct to surgical resection and in the management of patients who are not surgical candidates. Overall, the management of hepatic metastasis from colorectal cancers requires a multimodal approach.",
keywords = "Cancer, Colorectal, Hepatic, Metastasis",
author = "Sharad Sharma and Cemalettin Camci and Nicolas Jabbour",
year = "2008",
doi = "10.1007/s00534-008-1350-x",
language = "English (US)",
volume = "15",
pages = "570--580",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Management of hepatic metastasis from colorectal cancers

T2 - An update

AU - Sharma, Sharad

AU - Camci, Cemalettin

AU - Jabbour, Nicolas

PY - 2008

Y1 - 2008

N2 - Approximately 50%-60% of patients with colorectal cancers will develop liver lesions in their life span. Despite the potential of surgical resection to provide long-term survival in this subset of patients, only 15%-20% are found to be resectable. The introduction of new neoadjuvant chemotherapeutic agents and the expanding criteria of resection have enhanced the overall 5-year survival from 30% to 60% in the past decade. The use of technical innovations such as staged resection; portal vein embolization, and repeat resection have allowed higher resection rates in patients with bilobar disease. Extrahepatic primary and liver-exclusive recurrent disease no longer represent an absolute contraindication to resection. The role of regional therapy using hepatic arterial infusion is being redefined for liver-exclusive unresectable disease. Adjuvant chemotherapy in combination with regional therapies is being looked at from fresh perspectives. Ablative approaches have gained a firm role both as an adjunct to surgical resection and in the management of patients who are not surgical candidates. Overall, the management of hepatic metastasis from colorectal cancers requires a multimodal approach.

AB - Approximately 50%-60% of patients with colorectal cancers will develop liver lesions in their life span. Despite the potential of surgical resection to provide long-term survival in this subset of patients, only 15%-20% are found to be resectable. The introduction of new neoadjuvant chemotherapeutic agents and the expanding criteria of resection have enhanced the overall 5-year survival from 30% to 60% in the past decade. The use of technical innovations such as staged resection; portal vein embolization, and repeat resection have allowed higher resection rates in patients with bilobar disease. Extrahepatic primary and liver-exclusive recurrent disease no longer represent an absolute contraindication to resection. The role of regional therapy using hepatic arterial infusion is being redefined for liver-exclusive unresectable disease. Adjuvant chemotherapy in combination with regional therapies is being looked at from fresh perspectives. Ablative approaches have gained a firm role both as an adjunct to surgical resection and in the management of patients who are not surgical candidates. Overall, the management of hepatic metastasis from colorectal cancers requires a multimodal approach.

KW - Cancer

KW - Colorectal

KW - Hepatic

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=56249124251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249124251&partnerID=8YFLogxK

U2 - 10.1007/s00534-008-1350-x

DO - 10.1007/s00534-008-1350-x

M3 - Article

C2 - 18987925

AN - SCOPUS:56249124251

VL - 15

SP - 570

EP - 580

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 6

ER -